Pulse Biosciences, Inc. (PLSE) Reports Q4 Loss of $0.51

Pulse Biosciences, Inc. (NASDAQ: PLSE) reported Q4 EPS of ($0.51), versus ($0.53) reported last year.

“We are pleased with our accomplishments over the past year in advancing our proprietary CellFX System and look forward to achieving key commercialization milestones in 2019,” said Darrin Uecker, Pulse Biosciences’ President and Chief Executive Officer.

For earnings history and earnings-related data on Pulse Biosciences, Inc. (PLSE) click here.

You May Also Be Interested In

• Nucor projects Q3 2026 earnings above prior year, below estimates
• Cargojet Inc. (CJT:CN) (CGGJF) PT Raised to $128 at TD Cowen, maintains bullish call
• Astrana Health (ASTH) Mentioned as short at Glass House